Last reviewed · How we verify
NCT03033927
Predicting Effective Therapy in Pancreatic Cancer
trial testing CTC isolocation and analysis in Pancreatic Cancer in 74 participants. Participants enrolled and being followed up; not accepting new ones.
24 January 2026
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 74 |
| Start date | 24 January 2017 |
| Primary completion | 24 January 2026 |
| Estimated completion | 24 January 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- CTC isolocation and analysis
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Pancreatic Cancer or Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A conduit to metastasis: circulating tumor cell biology.
Micalizzi DS, Maheswaran S, Haber DA. · · 2017 · cited 320× · PMID 29051388 · DOI 10.1101/gad.305805.117 -
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz BA, O'Reilly EM. · · 2018 · cited 30× · PMID 29269376 · DOI 10.1158/1078-0432.ccr-16-3169 -
Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.
Wu X, Zhu L, Ma PC. · · 2018 · cited 17× · PMID 30231325 · DOI 10.1200/edbk_199767 -
Pancreas cancer: Therapeutic trials in metastatic disease.
Smithy JW, O'Reilly EM. · · 2021 · cited 13× · PMID 33831245 · DOI 10.1002/jso.26359 -
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Yu KH, Ricigliano M, McCarthy B, Chou JF, et al · · 2018 · cited 13× · PMID 30477242 · DOI 10.3390/cancers10120467 -
Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers.
Jacobson RA, Munding E, Hayden DM, Levy M, et al · · 2019 · cited 12× · PMID 31412682 · DOI 10.3390/cancers11081164 -
Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?
Radhakrishnan V, Kaifi JT, Suvilesh KN. · · 2024 · cited 8× · PMID 38398206 · DOI 10.3390/cancers16040816 -
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Yu KH, Park J, Mittal A, Abou-Alfa GK, et al · · 2022 · cited 7× · PMID 35647938 · DOI 10.1002/cncr.34269
Verify or expand the search:
- PubMed search for NCT03033927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03033927 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03033927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing